Table 2 Modality and dose of GO therapy and treatment responses in 12 children with relapsed/refractory myeloid leukemia
Nr | Disease status | Nb of GO courses | GO dose/course | BM before GO % * | Diag/GO (days) | Response | GO toxicity (NCI-CTC) ¥ | Further treatment | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
#1 | De novo refractory | 1 | 1 × 9 mg/m2 (d1) | 40 | 335 | DP | Anaphylaxis Transient grade IV hyperbili. Grade III transa. elevation | None | V from JMML |
#2 | Refractory relapse | 1 | 1 × 9 mg/m2 (d1) | 98 | 250 | DP | No | None | V from AML |
#3 | Post-SCT 2nd relapse | 1 | 3 × 3 mg/m2 (d1,d4,d7) | 49 | 555 | DP | Grade III febrile neutropenia Grade III transa. elevation | None | V from AML |
#4 | Refractory relapse | 1 | 3 × 3 mg/m2 (d1,d4,d7) | 43 | 177 | DP | Grade II vomiting Grade III febrile neutropenia Grade II stomatitis | None | V from AML |
#5 | De novo refractory | 1 | 3 × 3 mg/m2 (d1,d4,d7) | 45 | 667 | CRp (d28) | No | MUD-SCT | V from SCT |
#6 | Refractory relapse | 1 | 3 × 3 mg/m2 (d1,d4,d7) | 73 | 579 | DP | Grade II stomatitis | None | V from AML |
#7 | De novo refractory | 1 | 1 × 9 mg/m2 (d1) | 59 | 145 | DP | Septic shock Grade II vomiting Grade I fever | None | V from AML |
#8 | Refractory relapse | 1 | 3 × 3 mg/m2 (d1,d4,d7) | 96 | 298 | DP | Grade II vomiting Grade I fever | None | V from AML |
#9 | Refractory relapse | 2 | 3 × 3 mg/m2 (d1,d4,d7) and 2 × 3 mg/m2 ‡ | 86 | 162 | CR (d39) | No | MUD-SCT | V from AML § |
#10 | Refractory relapse | 1 | 2 × 9 mg/m2 (d1,d14) | 25 | 357 | DP | Grade III febrile neutropenia Grade II transa elevation Grade II hyperbilirubinemia Grade III acute cholecystitis Grade IV hemorragic cystitis | None | V from AML |
#11 | Refractory relapse | 1 | 2 × 7.5 mg/m2 (d1,d16) | 20 | 513 | CRp (d24) | Grade II fever Grade II vomiting | Haplo-SCT | V from AML |
#12 | Refractory relapse | 1 | 6 mg/m2 (d1)+9 mg/m2 (d16) | 35 | 1367 | DP | Grade II pancreatitis Grade II fever Grade II vomiting | Arsenic clofarabin. | Alive in PR ♣ |